In contrast to the low-risk HPV types, the high-risk Alpha PVs not only drive cell cycle entry in the upper epithelial layers, but (for reasons which are not yet clear) have E6 and E7 proteins that can stimulate the proliferation of infected basal cells and cause neoplasia. This additional characteristic reflects differences in the viral proteins but also differences in the way that the viral proteins are expressed in the basal layer and above. Indeed, it is generally

accepted that deregulated expression of these cell cycle regulators underlies neoplasia and the eventual progression to cancer in individuals who cannot resolve their infection. Although most work to date has focused on the study of high-risk HPV types, and in particular on HPV16 and 18, there will be a need in future to better understand the different Epacadostat mouse risks associated

with different high-risk types, and to more fully understand the molecular pathways that they subvert. Such approaches are Dabrafenib nmr expected to lead us eventually to the development of better strategies for disease treatment (i.e., targeted antivirals or immunotherapeutics), which are necessary to complement current methods of disease management (i.e., prophylactic vaccination, screening, surgical ablation or local immune modulation). It will also be important to consider high-risk HPV-associated diseases at sites other than the cervix, and to understand the mechanisms by which low-risk HPV types can give almost rise to papillomatosis and, rarely, cancer. Developing

an understanding of the natural history of the Gamma and Beta HPV types both within disease and cancer, will also be an important part of this. The E4/MCM staining shown in Fig. 7A was produced by Heather Griffin (NIMR, London, UK) using a tissue section prepared as part of an ongoing collaboration with Robert Jach, Krzysztof Okoń and Grzegorz Dyduch at the Jagiellonian University Medical College, Krakow, Poland. The LCM images shown in Fig. 7B was produced by Rene Bax and David Jenkins at DDL, Voorburg, Holland. IG Bravo is partially supported by public grants from the disappeared Spanish Ministry for Science and Innovation (BFU2009-06702-E/BMC, CGL2010-16713) and from the Spanish “Red Temática de Investigación Cooperativa en Cáncer” (RTIC RD06/0020/0095). Disclosed potential conflicts of interest JD: Is supported by the UK Medical Research Council, has recently acted as consultant for SPMSD, Merck and Roche, and has received research support from SPMSD, GSK and the Wellcome Trust. WQ: Has received research funding from GSK. LB: Has received research support from the Associazione Italiana per la Ricerca sul Cancro, Telethon, the Association for International Cancer Research and the Wellcome Trust. IGB: Has no conflict of interest. The Unit of Infections and Cancer at the ICO is involved in HPV vaccine trials and epidemiological studies sponsored by GlaxoSmithKline, Merck and Sanofi Pasteur MSD and screening and HPV testing trials partially supported by Qiagen.